A Zoufaly1, J Jochum2, R Hammerl3, N Nassimi3, Y Raymond4, G D Burchard3, S Schmiedel2, J F Drexler5, N K Campbell6, N Taka4, C Awasom4, K J Metzner6, J van Lunzen2, T Feldt7. 1. Infectious Diseases Unit, Department of Medicine 1, University Medical Center Hamburg-Eppendorf, Hamburg, Germany Department of Medicine 4, Kaiser Franz Josef Hospital, Vienna, Austria alex_zoufaly@yahoo.com. 2. Infectious Diseases Unit, Department of Medicine 1, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. 3. Clinical Research Unit, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany. 4. Bamenda Regional Hospital, Bamenda, Cameroon. 5. Institute of Virology, University of Bonn, Bonn, Germany. 6. Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland. 7. Clinical Research Unit, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany Clinic of Gastroenterology, Hepatology and Infectious Diseases, University Hospital Düsseldorf, Düsseldorf, Germany.
Abstract
OBJECTIVES: The aim of this study was to describe clinical and virological outcomes in therapy-naive HIV-1-positive patients treated in a routine ART programme in rural Cameroon. METHODS: In a prospective cohort, 300 consecutive patients starting first-line ART were enrolled and followed for 12 months. Among 238 patients with available viral load data at Month 12, logistic regression was used to analyse risk factors for virological failure (≥1000 HIV RNA copies/mL) including clinical, immunological and virological parameters, as well as data on drug adherence. Population sequencing was performed to detect the presence of drug-resistance mutations in patients with virological failure at Month 12; minority drug-resistance mutations at baseline were analysed using next-generation sequencing in these patients and matched controls. RESULTS: At Month 12, 38/238 (16%) patients experienced virological failure (≥1000 HIV RNA copies/mL). Patients with virological failure were younger, had lower CD4 cell counts and were more often WHO stage 3 or 4 at baseline. Sixty-three percent of patients with virological failure developed at least one drug-resistance mutation. The M184V (n = 18) and K103N (n = 10) mutations were most common. At baseline, 6/30 patients (20%) experiencing virological failure and 6/35 (17%) matched controls had evidence of minority drug-resistance mutations using next-generation sequencing (P = 0.77). Lower CD4 count at baseline (OR per 100 cells/mm(3) lower 1.41, 95% CI 1.02-1.96, P = 0.04) and poorer adherence (OR per 1% lower 1.05, 95% CI 1.02-1.08, P < 0.001) were associated with a higher risk of virological failure. Unavailability of ART at the treatment centre was the single most common cause for incomplete adherence. CONCLUSIONS: Virological failure after 1 year of ART was not associated with minority drug resistance at baseline but with incomplete adherence. Strategies to assure adherence and uninterrupted drug supplies are pivotal factors for therapy success.
OBJECTIVES: The aim of this study was to describe clinical and virological outcomes in therapy-naive HIV-1-positivepatients treated in a routine ART programme in rural Cameroon. METHODS: In a prospective cohort, 300 consecutive patients starting first-line ART were enrolled and followed for 12 months. Among 238 patients with available viral load data at Month 12, logistic regression was used to analyse risk factors for virological failure (≥1000 HIV RNA copies/mL) including clinical, immunological and virological parameters, as well as data on drug adherence. Population sequencing was performed to detect the presence of drug-resistance mutations in patients with virological failure at Month 12; minority drug-resistance mutations at baseline were analysed using next-generation sequencing in these patients and matched controls. RESULTS: At Month 12, 38/238 (16%) patients experienced virological failure (≥1000 HIV RNA copies/mL). Patients with virological failure were younger, had lower CD4 cell counts and were more often WHO stage 3 or 4 at baseline. Sixty-three percent of patients with virological failure developed at least one drug-resistance mutation. The M184V (n = 18) and K103N (n = 10) mutations were most common. At baseline, 6/30 patients (20%) experiencing virological failure and 6/35 (17%) matched controls had evidence of minority drug-resistance mutations using next-generation sequencing (P = 0.77). Lower CD4 count at baseline (OR per 100 cells/mm(3) lower 1.41, 95% CI 1.02-1.96, P = 0.04) and poorer adherence (OR per 1% lower 1.05, 95% CI 1.02-1.08, P < 0.001) were associated with a higher risk of virological failure. Unavailability of ART at the treatment centre was the single most common cause for incomplete adherence. CONCLUSIONS:Virological failure after 1 year of ART was not associated with minority drug resistance at baseline but with incomplete adherence. Strategies to assure adherence and uninterrupted drug supplies are pivotal factors for therapy success.
Authors: Valerie F Boltz; Wei Shao; Michael J Bale; Elias K Halvas; Brian Luke; James A McIntyre; Robert T Schooley; Shahin Lockman; Judith S Currier; Fred Sawe; Evelyn Hogg; Michael D Hughes; Mary F Kearney; John M Coffin; John W Mellors Journal: JCI Insight Date: 2019-10-03
Authors: Herbert A Mbunkah; Silvia Bertagnolio; Raph L Hamers; Gillian Hunt; Seth Inzaule; Tobias F Rinke De Wit; Roger Paredes; Neil T Parkin; Michael R Jordan; Karin J Metzner Journal: J Infect Dis Date: 2020-04-27 Impact factor: 5.226
Authors: Charlotte Boullé; Emilande Guichet; Charles Kouanfack; Avelin Aghokeng; Benjamin Onambany; Catherine Massama Ikaka; Emile Ngock; Landry Tsoumsta; Philippe Msellati; Eitel Mpoudi-Ngolé; Martine Peeters; Eric Delaporte; Christian Laurent Journal: Open Forum Infect Dis Date: 2016-12-20 Impact factor: 3.835
Authors: Verónica Martín; Celia Perales; María Fernández-Algar; Helena G Dos Santos; Patricia Garrido; María Pernas; Víctor Parro; Miguel Moreno; Javier García-Pérez; José Alcamí; José Luis Torán; David Abia; Esteban Domingo; Carlos Briones Journal: PLoS One Date: 2016-12-13 Impact factor: 3.240
Authors: Patrycja Machnowska; Andrea Hauser; Karolin Meixenberger; Britta Altmann; Norbert Bannert; Eva Rempis; Alexandra Schnack; Sarah Decker; Vera Braun; Priscilla Busingye; John Rubaihayo; Gundel Harms; Stefanie Theuring Journal: PLoS One Date: 2017-05-31 Impact factor: 3.240